- Cellipont Bioservices and Mongoose Bio sign agreement for process development and manufacturing of MGB-001 TCR-T Cell Therapy.
- MGB-001 targets solid tumors with epigenetically reprogrammed T cells, leveraging artificial intelligence for precision treatment.
Cellipont Bioservices has entered into an agreement with biopharmaceutical company Mongoose Bio to support the technology transfer, process development, and clinical-grade manufacturing of Mongoose’s autologous TCR-T cell therapy, MGB-001. The partnership will focus on delivering this advanced therapy, designed to target solid tumors, to clinical trials.
The MGB-001 therapy, Mongoose Bio’s lead candidate, is based on a reprogrammed T cell receptor (TCR) targeting immunogenic peptides expressed in various solid cancers. Mongoose Bio’s proprietary technology integrates generative artificial intelligence (Gen AI) to improve antigen discovery and T cell engineering, aiming to enhance therapeutic efficacy.
Cellipont Bioservices, a contract development and manufacturing organisation (CDMO), will handle the manufacturing of MGB-001 under cGMP conditions. “We’re pleased to be partnering with Mongoose Bio on their MGB-001 TCR-T Cell Therapy program,” said Mike O’Mara, COO of Cellipont Bioservices. “We look forward to collaborating and working with their team to deliver this novel cell therapy to cancer patients.”
Neil Warma, CEO of Mongoose Bio, expressed confidence in the collaboration, stating, “Cellipont is a strong partner for us and has excellent manufacturing capabilities to support advancing our lead candidate MGB-001 into the clinic.” Warma highlighted that the therapy is intended for patients who have not responded to existing treatments across multiple tumour types.
Overview of outsourcing trends 
